New potential drug for type 2 diabetes treatment explored at MAX IV
A recent finding has indicated that the amino acid-derived metabolite imidazole propionate (ImP) in patients with type 2 diabetes could contribute to impaired glucose tolerance and reduced insulin signalling. The…